Novo Nordisk investor relations material
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company operates through two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment offers insulins, GLP-1 and related delivery systems and devices, other protein related products, oral antidiabetic products, and obesity. The Biopharmaceuticals segment provides haemophilia care products that include recombinant Factor VIII and Factor IX therapies for the treatment of haemophilia A and B; plasma derived therapies for the treatment of inhibitor patients with haemophilia A and B; monoclonal antibodies for the prevention of bleeding in patients undergoing surgery; extended half-life coagulation factors under development to treat haemophilia; and soluble coagulation factor receptor fuse protein.